Related references
Note: Only part of the references are listed.Prepandemic Immunization for Novel Influenza Viruses, Swine Flu Vaccine, Guillain-Barre Syndrome, and the Detection of Rare Severe Adverse Events
David Evans et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Managing and Reducing Uncertainty in an Emerging Influenza Pandemic.
Marc Lipsitch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza
Nicolas Collin et al.
VACCINE (2009)
Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix (TM)] - A review of its use as an active immunization against influenza A subtype H5N1 virus
Natalie J. Carter et al.
BIODRUGS (2008)
Pandemic H5N1 influenza vaccine development: an update
Hana M. El Sahlyt et al.
EXPERT REVIEW OF VACCINES (2008)
An adjuvanted, low-dose, pandemic influenza a (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults
Karin Levie et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture
Hartmut J. Ehrlich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
Isabel Leroux-Roels et al.
PLOS ONE (2008)
Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine
Benoit Baras et al.
PLOS ONE (2008)
New vaccine approaches for seasonal and pandemic influenza
Bram Palache
VACCINE (2008)
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial
Isabel Leroux-Roels et al.
LANCET (2007)
Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate
Steven Riley et al.
PLOS MEDICINE (2007)
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial
Jiangtao Lin et al.
LANCET (2006)
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
Jean-Louis Bresson et al.
LANCET (2006)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
JJ Treanor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Drug therapy - Neuraminidase inhibitors for influenza
A Moscona
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: A potential priming strategy
I Stephenson et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Influenza epidemics in the United States, France, and Australia, 1972-1997
C Viboud et al.
EMERGING INFECTIOUS DISEASES (2004)
Early administration of oral oseltamivir increases the benefits of influenza treatment
FY Aoki et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Share Paper
